Get the Stockscreener App
15.98
1.96%
-0.32
After Hours:
16.18
0.20
+1.25%
Viridian Therapeutics Inc stock is traded at $15.98, with a volume of 1.26M.
It is down -1.96% in the last 24 hours and down -4.99% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
See More
Previous Close:
$16.30
Open:
$16.29
24h Volume:
1.26M
Relative Volume:
0.45
Market Cap:
$1.76B
Revenue:
$70.92M
Net Income/Loss:
$-342.21M
P/E Ratio:
-4.245
EPS:
-3.7644
Net Cash Flow:
$-304.30M
1W Performance:
-2.02%
1M Performance:
-4.99%
6M Performance:
-51.35%
1Y Performance:
+0.25%
1-Day Range:
$15.96
$16.45
1-Week Range:
$15.50
$16.72
52-Week Range:
$13.18
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
15.98 | 1.80B | 70.92M | -342.21M | -304.30M | -3.7644 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Reiterated | Wedbush | Outperform |
| Dec-03-25 | Initiated | William Blair | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Aug-25-25 | Resumed | Jefferies | Buy |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $35 - Moomoo
VRDN: Approval expected June 30, with launch-ready teams and strong clinical differentiation - TradingView
VRDN News | VIRIDIAN THERAPEUTICS INC (NASDAQ:VRDN) - ChartMill
Viridian Therapeutics stock tumbles after Amgen Tepezza data By Investing.com - Investing.com UK
Viridian Therapeutics stock tumbles after Amgen Tepezza data - Investing.com
VRDN: Ready for TED drug launch in 2026, aiming for broad access and major market expansion - TradingView
[8-K] Viridian Therapeutics, Inc.\DE Reports Material Event - Stock Titan
Viridian ties up WuXi supply deal ahead of TED decision - The Pharma Letter
How Investors May Respond To Viridian Therapeutics (VRDN) Debt Repayment And WuXi Manufacturing Pact - Sahm
Viridian Therapeutics (VRDN) Edges Higher Amid Modest Trading ActivityInsider Buying Alerts - newsline.com
Viridian Therapeutics (NASDAQ: VRDN) retires $55.1M Hercules term loan years early - Stock Titan
Viridian Therapeutics, Inc. Announces Voluntary Prepayment and Termination of Loan Agreement - marketscreener.com
Viridian Therapeutics to Present at Goldman Sachs and Jefferies Healthcare Conferences in June - geneonline.com
Viridian Therapeutics to Participate in Upcoming June 2026 Investor Conferences - BioSpace
(VRDN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Viridian Therapeutics to Participate in Upcoming June Investor Conferences - The Joplin Globe
PDUFA decision nears as Viridian Therapeutics (VRDN) advances TED pipeline and reports Q1 results - MSN
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Viridian Therapeutics, Inc. has reached an agreement with WuXi Biologics, which will manufacture and supply Viridian's investigational drug Veligrotug. - Bitget
Viridian Therapeutics signs manufacturing deal with WuXi Biologics for thyroid eye disease drug - marketscreener.com
Viridian therapeutics enters commercial manufacturing agreement with Wuxi biologics on May 24, 2026 - marketscreener.com
Viridian (VRDN) secures WuXi Biologics pact for long-term veligrotug manufacturing - Stock Titan
Viridian Therapeutics, Inc. Enters Into Commercial Manufacturing Services Agreement With WuXi Biologics - marketscreener.com
Viridian Therapeutics(VRDN) Stock Options Chain | Quotes & News - Moomoo
Does Viridian’s Upsized Note and Equity Offering Change The Bull Case For Viridian Therapeutics (VRDN)? - Sahm
Viridian Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Thyroid Eye Disease PipelineAnalyst Consensus Shift - newsline.com
Viridian Therapeutics prices upsized $350M concurrent stock and convertible notes offerings - MSN
Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M - Insider Monkey
Viridian Therapeutics releases topline phase 3 TED data elegrobart - Eyes On Eyecare
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - AOL.com
Viridian Therapeutics launches $250M concurrent debt and equity offerings - MSN
HighVista Strategies Sells 238,243 Shares of Viridian Therapeutics in Q1 2026News and Statistics - IndexBox
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - The Motley Fool
Why is Viridian Therapeutics stock sinking Monday? - MSN
VRDN: Wedbush Maintains Rating but Lowers Price Target | VRDN St - GuruFocus
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Liquidity Mapping Around (VRDN) Price Events - Stock Traders Daily
VRDN Maintained by Evercore ISI Group -- Price Target Lowered to $26 - GuruFocus
Viridian Therapeutics Analyst Ratings and Price Targets | NASDAQ:VRDN - Benzinga
Viridian Therapeutics Inc (VRDN) Stock Price, Quote, News & History - Benzinga
Bellevue Group (VRDN) files Schedule 13G for 6.6% ownership - Stock Titan
Viridian Therapeutics stock (US92769V1044): Q1 earnings beat and Phase 3 data boost - AD HOC NEWS
Fairmount Healthcare Fund II invests $20m in Viridian Therapeutics By Investing.com - Investing.com Australia
Viridian Therapeutics(VRDN.US) 10% Shareholder Buys US$20 Million in Common Stock - Moomoo
Fairmount-linked fund boosts Viridian (VRDN) stake with 1.18M-share open-market buy - Stock Titan
Fairmount boosts Viridian Therapeutics (VRDN) stake to 14.04% after $20M share purchase - Stock Titan
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $39 - Moomoo
VRDN6389238 Bond Coupon Analysis — Rate & Payments - TradingView
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):